The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease
Open accessAbstract
BACKGROUND: Hypertension develops early in patients with autosomal dominant polycystic kidney disease (ADPKD) and is associated with disease progression. The renin-angiotensin-aldosterone system (RAAS) is implicated in the pathogenesis of hypertension in patients with ADPKD. Dual blockade of the RAAS may circumvent compensatory mechanisms that limit the efficacy of monotherapy with an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II-receptor blocker (ARB). METHODS: In this double-blind, placebo-controlled trial, we randomly assigned 486 patients, 18 to 64 years of age, with ADPKD (estimated glomerular filtration rate [GFR], 25 to 60 ml per minute per 1.73 m(2) of body-surface area) to receive an ACE inhibitor (lisinopril) and placebo or lisinopril and an ARB (telmisartan), with the doses adjusted to achieve a blood pressure of 110/70 to 130/80 mm Hg. The composite primary outcome was the time to death, end-stage renal disease, or a 50% reduction from the baseline estimated GFR. Secondary outcomes included the rates of change in urinary aldosterone and albumin excretion, frequency of hospitalizations for any cause and for cardiovascular causes, incidence of pain, frequency of ADPKD-related symptoms, quality of life, and adverse study-medication effects. Patients were followed for 5 to 8 years. RESULTS: There was no significant difference between the study groups in the incidence of the composite primary outcome (hazard ratio with lisinopril-telmisartan, 1.08; 95% confidence interval, 0.82 to 1.42). The two treatments controlled blood pressure and lowered urinary aldosterone excretion similarly. The rates of decline in the estimated GFR, urinary albumin excretion, and other secondary outcomes and adverse events, including hyperkalemia and acute kidney injury, were also similar in the two groups. CONCLUSIONS: Monotherapy with an ACE inhibitor was associated with blood-pressure control in most patients with ADPKD and stage 3 chronic kidney disease. The addition of an ARB did not alter the decline in the estimated GFR. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; HALT-PKD [Study B] ClinicalTrials.gov number, NCT01885559.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Seber, G. A. F., & Wild, C. J. (1989) · Wiley Series in Probability and Statistics · doi:10.1002/0471725315 · Cited by 1,962
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citationMann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
On the regression analysis of multivariate failure time data
PRENTICE, R. L., WILLIAMS, B. J., & PETERSON, A. V. (1981) · Biometrika · doi:10.1093/biomet/68.2.373 · Cited by 1,333
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., de Zeeuw, D., Shahinfar, S., Toto, R., Levey, A. S., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-4-200308190-00006 · Cited by 1,157
Kunz, R., Friedrich, C., Wolbers, M., & Mann, J. F. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00190 · Cited by 717
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587
Ravine, D., Sheffield, L., Danks, D. M., Gibson, R. N., Walker, R. G., & Kincaid-Smith, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92026-5 · Cited by 564
Autosomal Dominant Polycystic Kidney Disease
Grantham, J. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0804458 · Cited by 543
Self-citationBlood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
Schrier, R. W., Abebe, K. Z., Perrone, R. D., Torres, V. E., Braun, W. E., Steinman, T. I., Winklhofer, F. T., Brosnahan, G., Czarnecki, P. G., Hogan, M. C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402685 · Cited by 528
Self-citation(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.46 · Cited by 521
The Renin–Angiotensin–Aldosterone System and Autosomal Dominant Polycystic Kidney Disease
Chapman, A. B., Johnson, A., Gabow, P. A., & Schrier, R. W. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010183231602 · Cited by 398
Self-citationKlahr, S., Breyer, J. A., Beck, G. J., Dennis, V. W., Hartman, J. A., Roth, D., Steinman, T. I., Wang, S. R., & Yamamoto, M. E. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v5122037 · Cited by 251
Self-citationMacKinnon, M., Shurraw, S., Akbari, A., Knoll, G. A., Jaffey, J., & Clark, H. D. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.04.077 · Cited by 246
Shared parameter models for the joint analysis of longitudinal data and event times
Vonesh, E. F., Greene, T., & Schluchter, M. D. (2006) · Statistics in Medicine · doi:10.1002/sim.2249 · Cited by 176
Dual renin-angiotensin system blockade at optimal doses for proteinuria
Laverman, G. D., Navis, G., Henning, R. H., De Jong, P. E., & De Zeeuw, D. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00536.x · Cited by 170
Group sequential procedures: Calendar versus information time
Lan, K. K. G., & Demets, D. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780081003 · Cited by 168
Schrier, R. W. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080882 · Cited by 157
Self-citationThe intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease
Loghman‐Adham, M., Soto, C. E., Inagami, T., & Cassis, L. A. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00370.2003 · Cited by 155
The HALT Polycystic Kidney Disease Trials: Design and Implementation
Chapman, A. B., Torres, V. E., Perrone, R. D., Steinman, T. I., Bae, K. T., Miller, J. P., Miskulin, D. C., Rahbari-Oskoui, F. F., Masoumi, A., Hogan, M. C., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04310709 · Cited by 152
Self-citationEcder, T., Chapman, A. B., Brosnahan, G., Edelstein, C. L., Johnson, A. M., & Schrier, R. W. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70195-8 · Cited by 138
Self-citationSynthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease
Torres, V. E., Donovan, K. A., Scicli, G. M., Holley, K. E., Thibodeau, S. N., Carretero, O. A., Inagami, T., McAteer, J. A., & Johnson, C. M. (1992) · Kidney International · doi:10.1038/ki.1992.297 · Cited by 138
Self-citationJennings, D. L., Kalus, J. S., Coleman, C. I., Manierski, C., & Yee, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02097.x · Cited by 124
The anatomy of the renin-secreting cell in adult polycystic kidney disease
Graham, P., & Lindop, G. B. M. (1988) · Kidney International · doi:10.1038/ki.1988.115 · Cited by 121
Analysis of baseline parameters in the HALT polycystic kidney disease trials
Torres, V. E., Chapman, A. B., Perrone, R. D., Bae, K. T., Abebe, K. Z., Bost, J. E., Miskulin, D. C., Steinman, T. I., Braun, W. E., Winklhofer, F. T., et al. (2011) · Kidney International · doi:10.1038/ki.2011.411 · Cited by 94
Self-citationNo effect of enalapril on progression in autosomal dominant polycystic kidney disease
van Dijk, M. A., Breuning, M. H., Duiser, R., van Es, L. A., & Westendorp, R. G. J. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg417 · Cited by 86
Torres, V. E., Wilson, D. M., Burnett, J. C. J., JOHNSON, C. M., & Offord, K. P. (1991) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61724-8 · Cited by 74
Self-citationSusantitaphong, P., Sewaralthahab, K., Balk, E. M., Eiam‐Ong, S., Madias, N. E., & Jaber, B. L. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hps038 · Cited by 71
Zeltner, R., Poliak, R., Stiasny, B., Schmieder, R. E., & Schulze, B. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm731 · Cited by 54
Steinman, T. I. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm865 · Cited by 52
Self-citationBlood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
Benck, U., Krüger, B., & Schmitt, W. H. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1500332 · Cited by 34
Cited by
Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,031
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Self-citationAutosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Self-citationChapman, A. B., Devuyst, O., Eckardt, K.-U., Gansevoort, R. T., Harris, T., Horie, S., Kasiske, B. L., Odland, D., Pei, Y., Perrone, R. D., et al. (2015) · Kidney International · doi:10.1038/ki.2015.59 · Cited by 611
Self-citationXie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.011 · Cited by 479
Metadata
- Authors
- Torres, V. E., Abebe, K. Z., Chapman, A. B., Schrier, R. W., Braun, W. E., Steinman, T. I., Winklhofer, F. T., Brosnahan, G., Czarnecki, P. G., Hogan, M. C., Miskulin, D. C., Rahbari-Oskoui, F. F., Grantham, J. J., Harris, P. C., Flessner, M. F., Moore, C. G., & Perrone, R. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-11
- Volume
- 371
- Issue
- 24
- Pages
- 2267-2276
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965644948
- Cited by
- 291
- References
- 40
- FWCI
- 17.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.